I stand corrected. I also didn't realize they got royalties on anything Genzyme produced (re your
"...and will receive royalties in the event of commercial sales of products containing AAV vectors covered by the acquired intellectual property. GO GENZME!
I believe you are incorrect. AAV was sold to Genzyme, and everything arising from it except Mydicar and Glybera--and of course all Core Phage. But it should be enough. Cheers.
I don't know what you are talking about--although I appreciate everything you say. Of course standardized adoption by the entire financial industry would have to happen to make it work, But if IWS can provide the software to stop cyber fraud, when cybe fraud occurs, they should say, "If the industry adopted our software, this couldn't happen." And suggest some of the fused offerings which would end the problem.
So why didn't Miller have a press release saying they could stop it a frigging week ago!!!
This is regarding RSV vaccine GV2311: "To be clear however there is no current plan or the resources to advance the program into the clinic without a partner."
eighty patients @ $25k a patient is $2,000,000 for a phase 1. What am I missing?
They mention disolving the company TWICE before they mention it under risks. Can you imagine the law suits if they work something out from the price before the Q was released?
good, logical, stuff, buy why is she saying in a quarterly report that she can't find a buyer/partner
for breakthrough technology?
What does "midify" mean?
Quarter after quarter, Swirsky and Fischer (sp?) told us balance and hearing alone would be $200 million to GenVec in royalties, once approved and selling. Why don't they put everything else on hold and wait for Nov and atonal to begin paying off?